AstraZeneca plans to invest $50 billion in US by 2030
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
This collaboration aims to bridge India’s talent and translational gap in this rapidly growing field by equipping professionals with practical expertise in the manufacturing of advanced therapies.
Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
India’s nutraceutical industry is expected to reach over US$ 22 billion in 2025
The agreement includes plans for distribution, technology transfer, local manufacturing, new pharmaceutical product development
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
Subscribe To Our Newsletter & Stay Updated